Truist analyst David MacDonald raised the firm’s price target on HCA Healthcare to $270 from $240 and keeps a Buy rating on the shares as part of a broader research note on Hospitals. The analyst notes that his Q4 hospital survey suggests "decent utilization" with sequential improvement across care settings and a labor environment that is showing signs of improvement despite the "difficult backdrop".
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCA: